News
Public · Published
Amgen Q3 preview: What to expect
Amgen was scheduled to report third-quarter results on November 3 after the market closed. Analysts expected revenue of $10.07 billion, nearly 5% higher year over year, and earnings growth of 2.5%, while focusing on established-drug sales and growth from Tezspire and Repatha.
Published:
Updated:
What happened
Amgen was scheduled to report third-quarter results on November 3 after the market closed. Analysts expected revenue of $10.07 billion, nearly 5% higher year over year, and earnings growth of 2.5%, while focusing on established-drug sales and growth from Tezspire and Repatha.
Confirmed
Global impact / market context
The sales mix matters because continued declines in established products such as Prolia and Otezla could offset gains from newer or faster-growing drugs. That would affect whether overall revenue growth translates into stronger earnings, shaping investor expectations for Amgen’s future sales and cash generation.
Analyst inference
Analyst views were mixed: revenue estimates had 20 upward revisions and no downward revisions, while concern remained about erosion in established products. Last quarter, Prolia sales fell 32% year over year and Otezla sales fell 21%, making the upcoming results a test of whether growth elsewhere can compensate.
Confirmed
What to watch
- Check reported third-quarter revenue against the $10.07 billion analyst expectation; the result will show whether sales growth matched the forecast. Confirmed
- Look for updates on Prolia and Otezla sales, since further declines could reduce the contribution from established products and offset growth elsewhere. Analyst inference
- Compare Tezspire and Repatha sales with expectations to see whether growth in these drugs can help counter weaker established-product revenue. Analyst inference